Breaking News

Abide, Celgene In Drug Development Pact

By Kristin Brooks | February 28, 2014

To employ Abides technology platform for inflammation and immunology targets

Abide Therapeutics has entered into a strategic collaboration with Celgene Corp. to discover and develop new drugs in inflammation and immunology using Abides technology platform to selectively target serine hydrolases, one of the largest enzyme families involved in regulating physiology. Included in the collaboration is Abide's lead compound, AB101131, which is projected to enter first human studies in 2015. Abide expects to generate another three to four developmental candidates during the term of the collaboration.
Abide will receive an upfront payment and is eligible for additional milestones based on successful development. Celgene will take a small equity stake in Abide and will retain an exclusive option to acquire the company. Abide is also eligible to receive additional payments if Celgene exercises its option to license rights on the first two products that reach the clinic.
"This collaboration is a wonderful opportunity for Abide to focus in a therapeutic area that is ideal to explore the full potential of our therapeutic engine. Furthermore, this relationship will support Abide with Celgene's global expertise in discovery, development and commercialization of novel disease-altering therapies," said Alan Ezekowitz, president and chief executive officer of Abide Therapeutics. "The creative terms of this deal enable Abide to focus the components of the drug discovery continuum that we do best. We cannot wait to begin working closely with the team at Celgene."
"This collaboration with Abide illustrates our ongoing commitment to enable potentially disruptive technologies in the hands of talented drug hunters, here deployed in unique and powerful approach to target a validated but largely underexplored class of serine hydrolases," said Thomas Daniel, M.D., executive vice president and president, Global Research and Early Development at Celgene. "We are enthusiastic about the team, the technology, and the potential to create landmark therapies."

Related Contract Manufacturing:

blog comments powered by Disqus
  • Continuous Pharmaceutical Processes and Their Demands

    Continuous Pharmaceutical Processes and Their Demands

    Girish Malhotra, EPCOT International||April 5, 2016
    A look at the unique characteristics of continuous processes in pharmaceutical manufacturing.

  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.